
Opinion|Videos|April 1, 2024
Appropriateness of Initial Therapy for Chronic GvHD
Author(s)Corey S. Cutler, MD, MPH, FRCPC
Discussing the appropriateness of the initial therapy based on the NCCN guidelines for the given patient case.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5







































